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ABSTRACT 
Genetically engineered T-cells are being developed to perform a variety of therapeutic functions. However, no robust mechanisms 
exist to externally control the activity of T-cells at specific locations within the body. Such spatiotemporal control could help 
mitigate potential off-target toxicity due to incomplete molecular specificity in applications such as T-cell immunotherapy against 
solid tumors. Temperature is a versatile external control signal that can be delivered to target tissues in vivo using techniques such 
as focused ultrasound and magnetic hyperthermia. Here, we test the ability of heat shock promoters to mediate thermal actuation 
of genetic circuits in primary human T-cells in the well-tolerated temperature range of 37–42ºC, and introduce genetic 
architectures enabling the tuning of the amplitude and duration of thermal activation. We demonstrate the use of these circuits 
to control the expression of chimeric antigen receptors and cytokines, and the killing of target tumor cells. This technology 
provides a critical tool to direct the activity of T-cells after they are deployed inside the body. 
 
INTRODUCTION 
Unlike small molecule and biologic therapies, cells have a 
natural ability to navigate, persist and proliferate within the 
body, providing the potential for more targeted and sustained 
disease treatment. This potential is enhanced by the capacity 
of cells to probe, process, and respond to their environment 
and carry out a wide range of sophisticated behaviors, which 
can be engineered using the tools of synthetic biology1. Among 
the cell types being developed for therapy, T-cells are one of 
the most promising due to their central roles in cancer, 
infectious disease and autoimmune disorders, along with their 
relative ease of isolation, genetic modification and re-
engraftment. For example, this potential has been realized in 
T-cells engineered to express modularly targeted chimeric 
antigen receptors (CARs), allowing them to specifically 
eradicate cancers such as lymphomas bearing the CD19 
antigen2,3,4,5. Unfortunately, it has been challenging to 
translate these successful results into solid tumors, where CAR 
T-cells encounter a more immunosuppressive environment6 
and the risk of sometimes fatal on-target off-tumor toxicity due 
to the presence of tumor-overexpressed epitopes in healthy 
tissues7,8. Likewise, emerging approaches in which T-cells are 
used to treat autoimmune disease through local 
immunosuppression carry the risk of reducing important 
immune system activity outside the target tissues9. Existing 
strategies seeking to reduce off-target toxicity use additional 
target recognition elements10,11 or chemically triggered kill 
switches12,13,14. However, it can be difficult to ensure perfect 
recognition solely through molecular markers, and premature 
termination of T-cell therapy using kill-switches turns off their 
beneficial therapeutic action. 
Here we describe a cellular engineering approach to 
regulate the activity of therapeutic T-cells with greater 
specificity through a combination of molecular and physical 
actuation. This approach is designed to take advantage of the 
ability of technologies such as focused ultrasound (FUS) and 
magnetic hyperthermia to non-invasively deposit heat at 
precise locations in deep tissue15–18. By engineering thermal 
bioswitches allowing T-cells to sense small changes in 
temperature and use them as inputs for the actuation of genetic 
circuits, we enable these penetrant forms of energy to spatially 
control T-cell activity. Our approach is based on heat shock 
promoters (pHSP), which have been shown to drive gene 
expression in response to FUS-delivered heating19–21, but have 
not been tested in primary human T-cells. This is important 
because the behavior of pHSPs varies greatly between cell 
types and cellular states. In this study, we screen a library of 
pHSPs in primary T-cells and engineer gene circuits providing 
transient and sustained activation of gene expression in T-cells 
in response to brief thermal stimuli within the well-tolerated 
temperature range of 37–42ºC22–24. Our circuits incorporate 
feed-forward amplification, positive feedback and 
recombinase-based state switches. We demonstrate the use of 
these circuits to control the secretion of a therapeutic cytokine, 
expression of a CAR, and killing of target tumor cells. 
RESULTS 
Evaluating candidate pHSPs in primary T-cells. 
To enable thermal control of T-cell activity, we required a 
pHSP with robust switching behavior in primary human T-
cells. Given the variability in pHSP responses between cell 
types25, we decided to systematically evaluate the activity of 13 
different pHSPs in response to a 1-hour incubation at 42ºC. 
This thermal stimulus was chosen based on its tolerability by 
most tissues24, and the convenience of relatively short 
treatment durations in potential clinical scenarios. Our panel 
of pHSPs included nine human, three mouse, and one C. 
elegans promoters. The human promoters included four 
naturally occurring sequences (HSPB, HSPB’2, HSP A/A, 
HSP A/B), two modifications of HSPB’2 generated by varying 
the 5’ UTR (HSPB’1, HSPB’3), and three rational 
modifications of HSPB’2 (SynHSPB’1, SynHSPB’2, 
SynHSPB’3) inspired by a previously developed sensor of 
cellular stress26. Truncating HSPB’2 and leaving 192 base pairs 
resulted in SynHSPB’1. To lower potential baseline activity, 
the AP-1 binding site in SynHSPB’1 was mutated leading to 
SynHSPB’2. Duplicating SynHSPB’2 four times to increase 
the number of heat shock elements (HSE) resulted in 
SynHSPB’3. The three mouse-derived pHSPs were naturally 
occurring promoters. HSP16, derived from C. elegans, was first 
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described in 1986 and is rationally modified to form a minimal 
bidirectional promoter encompassing four HSE binding sites27. 
HSP16 excludes other transcription factor binding sites that 
typically exist in human promoters. We incorporated each 
pHSP into a standardized lentiviral construct in which the 
pHSP drives the expression of a green fluorescent protein 
(GFP), with a constitutively expressed blue fluorescent protein 
(BFP) serving as a marker of transduction (Fig. 1a).  
Of our 13 promoters, HSPB had the lowest baseline 
expression at 37ºC (Fig. 1b), an important property for 
minimizing activity in the absence of the thermal trigger. 
HSPB’1 showed the largest fold-change in gene expression, 
reflecting a combination of relatively low baseline expression 
and strong promoter activity when stimulated. Among the 
rationally engineered HSPB’2 variants, SYNHSPB’3 had a 
lower baseline than the natural promoter, albeit with lower 
maximum expression on activation. The rest of the human and 
mouse-derived promoters exhibited high baseline activity, 
resulting in their elimination from further experiments. Finally, 
the C. elegans minimal promoter exhibited acceptable 
performance and was included in further testing to investigate 
whether its minimal composition would be advantageous for 
specific activation in response to temperature. Based on these 
factors, we chose HSPB, HSPB’1, SynHSPB’3 and HSP16 as 
our starting points for further circuit engineering.  
 
Thermal parameters for pHSP activation. After 
identifying four candidate pHSPs, we tested their response to 
a range of induction parameters. To search for temperatures 
that provide rapid induction with minimal thermal burden to 
the cells, we incubated pHSP-transduced T-cells at 
temperatures ranging from 37ºC to 44ºC for 1 hour. All four 
promoters exhibited a significant increase in activity starting at 
42ºC (Fig. 2a). Increasing the induction temperature beyond 
this point resulted in a significant enhancement of 
transcriptional activity, but compromised cell viability (Fig. 
2b). To optimize induction with minimal cell damage, we 
chose 42ºC for further experiments. We note that unlike the 
gradual increase in gene expression observed with the 
mammalian promoters above 42ºC, HSP16 exhibited a large 
jump between this temperature and 43ºC, which may make it 
useful in future circuit engineering applications.  
To reduce the effect of thermal exposure on cell 
viability, we tested a pulsatile heating scheme with a 50% duty 
cycle28. In this scheme, cells underwent repeated cycles of 
heating to 42ºC for a fixed duration and an equal amount of 
time at 37ºC, adding up to a total of one hour at 42ºC over a 
two-hour treatment period. We varied the stimulation period 
between one minute and continuous heating for 60 min. This 
experiment revealed a trade-off between promoter activity 
(Fig. 2c) and cell viability (Fig. 2d), with shorter pulses 
reducing the former while increasing the latter. For the 
purposes of T-cell therapy, in which cells can expand after 
activation, we decided that a 40% decrease in cell viability was 
a suitable trade-off for improved activation, therefore selecting 
a continuous heating paradigm. This paradigm also simplifies 
the application of heating during therapy. We also investigated 
continuous stimulation durations ranging from 15 to 120 
minutes. Shorter induction enhanced viability (Fig. 2e) at the 
expense of lower gene expression (Fig. 2f), with a one-hour 
stimulation providing the optimal balance. We chose this 
stimulus paradigm for our subsequent experiments.  
 
Genetic circuits for amplified and sustained 
thermal activation. On their own, pHSPs drove a 
relatively small amount of transient protein expression upon 
induction. To enable the use of pHSPs in T-cell therapy 
applications, it is useful to amplify the output of pHSP-driven 
circuits. This would enable cells to, for example, release a 
relatively large therapeutic bolus after a single thermal 
stimulus. To achieve this goal, we implemented a feed-forward 
amplification circuit in which the pHSP drives an rtTA 
transactivator, which produces stronger transcriptional 
activation tunable with doxycycline. In addition, LNGFR was 
constitutively expressed to identify virally transfected cells (Fig. 
3a). Amplification circuits incorporating HSPB, HSPB’1, 
SynHSPB’3 and HSP16 all exhibited a substantial increase in 
their fold-induction, while only modestly elevating baseline 
expression. HSPB showed the best performance. To further 
tune the performance of the HSPB amplifier circuit, we 
designed constructs with reduced translation of the GFP by 
varying the Kozak sequence or inserting a micro open reading 
frame upstream29 (Fig. 3b). These modifications enabled the 
tuning of both the baseline expression and the maximal 
activation level. 
 
Figure 1 | Evaluating candidate pHSPs in primary T-cells (a) Illustration of the screening strategy used to characterize the behaviour 
of pHSPs. The viral construct used to assay pHSPs is shown, along with the promoters tested. LTR, long terminal repeat. (b) Mean fluorescence 
intensity 24 hours after a 1-hour incubation at 37°C or 42ºC, as measured via flow cytometry. The fold change between 37°C and 42°C is 
listed above each sample. Where not seen, error bars (±SEM) are smaller than the symbol. N=3 biological replicates for each sample. 
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 In some therapeutic scenarios, it is critical to prolong 
the therapeutic action of T-cells following a thermal induction 
treatment. This would eliminate the need to apply repeated 
stimuli to maintain treatment efficacy. To develop this 
capability, we established a positive feedback amplifier circuit 
by rearranging the elements of our feed-forward amplifier such 
that rtTA could drive its own expression in the presence of 
doxycycline (Fig. 3c). A similar design was previously tested in 
human cervical cancer HeLa cells30. The HSPB feedback 
circuit maintained its thermal induction level, and 
we were able to reduce baseline activity by tuning the Kozak 
sequence upstream of rtTA. In the current design, the output 
of the positive feedback circuit is lower than that of the feed-
forward amplifier, as expected from the GFP payload being 
placed after an IRES element. While we envision that such 
“low but steady” activity is desirable in many applications, a 
“high and steady” mode could in principle be achieved by 
exchanging the IRES for a 2A element. The dynamic 
expression profiles of our direct, feed-forward, and feedback 
HSPB circuits are compared in Fig. 3d, demonstrating 
prolonged expression with positive feedback.  
While the positive feedback circuit sustained 
expression for several days, this circuit can eventually turn off 
amid dilution or fluctuating expression of the transactivator. 
 
 
Figure 2 | Thermal parameters for pHSP activation. GFP expression from constructs driven by the HSPB, HSPB’1, SynHSPB’3 and 
HSP16F promoters (a, c, e) and T-cell viability (b, d, f) as a function of (a,b) induction temperature for a continuous 1 hour stimulus, (c,d) 
pulse duration of stimuli delivered with a 50% duty cycle alternating between 37ºC and 42ºC for a fixed thermal exposure of 1 hour, and (e,f) 
induction duration for continuous heating at 42ºC. Error bars represent ± SEM. N=3 biological replicates for each sample. 
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To establish a permanent thermal switch, we tested gene 
circuits in which we placed the expression of CRE 
recombinase under the control of candidate pHSPs (Fig. 3e). 
In these circuits, the pHSP-driven expression of CRE 
permanently toggles the circuit from expressing RFP to 
expressing anti-CD19 CAR by recombining the target vector. 
 
 
Figure 3 | Genetic circuits for amplified and sustained thermal activation. (a) Diagram illustrating the thermally trigged feed-
forward circuit (top). Fluorescence resulting from 1 hour induction at 37º or 42ºC for cells supplemented with doxycycline (bottom). (b) Diagram 
illustrating a feed-forward circuit driven by HSPB, <K> indicates varying kozak strength (top). Fluorescence resulting from 1 hour induction 
at 37º or 42ºC for cells supplemented with doxycycline (bottom). (c) Diagram illustrating the thermally trigged positive feedback circuit (top). 
Fluorescence resulting from 1 hour induction at 37º or 42ºC for cells supplemented with doxycycline (bottom). (d) Normalized expression 
monitored over seven days after 1 hour induction at 42ºC for direct HSPB-driven, feed-forward HSPB and positive-feedback HSPB circuits. 
Circuits have been modified to replace GFP with a destabilised version of the protein. (e) Illustration of the CRE based thermally triggered 
permanently stable switch designed to express CAR-CD19 upon induction. (f) Cells were either incubated at 37ºC or thermally stimulated for 
1 hour at 42ºC and analyzed 24 hours later to determine the number of activated cells. Error bars represent ± SEM. N=3 biological replicates 
for each sample. 
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When tested in a Jurkat T-cell line, these circuits demonstrated 
robust activation and minimal leakage (Fig. 3f). However, 
when tested in primary T-cells, we observed significantly 
higher levels of background activation (Fig. 3f). This may arise 
from the fact that immune stimulation is used to maintain 
primary T-cells cells in culture and our finding, discussed 
below, that pHSPs show significant background activity in 
stimulated primary T-cells. Taken together, these results 
suggest that in primary T-cells, feed-forward and feed-back 
amplification provide robust methods for thermal control of 
gene expression, while pHSP-controlled CRE recombination 
may produce an unacceptable level of irreversibly 
accumulating background activation. 
 
Temperature-activated cytokine release. To 
demonstrate the ability of our positive feedback circuit to 
sustain a therapeutically relevant function after thermal 
induction, we connected its output to the production of a 
cytokine. The local delivery of cytokines from engineered T-
cells would be useful in cancer immunotherapy by allowing T-
cells to secrete immune-stimulatory factors to remodel the 
tumor microenvironment and reduce immunosuppression. It 
would also be useful in treatments of autoimmune disease by 
allowing T-cells to secrete factors locally down-regulating the 
activity of endogenous immune cells. As a model cytokine, we 
selected IL-21, which has potential utility in cancer 
immunotherapy due to its ability to stimulate NK cells and 
CD8+ T-cells31,32. We incorporated human IL-21 in place of 
GFP in our positive feedback circuit (Fig. 4a). Without 
thermal induction, primary T-cells transduced with this circuit 
produced minimal IL-21. Once stimulated, the cells rapidly 
secreted IL-21, reaching a near-maximal level by 12 hours, 
and sustained activity for at least 5 days (Fig. 4a). The 
dependence of continued circuit function on doxycycline 
provides an additional layer of control, allowing the 
termination of therapy production at a desired time by 
removing doxycycline. To demonstrate this capability, we 
removed doxycycline 24 hours after cell induction, resulting in 
the abrogation of cytokine production by day five. The ability 
Figure 4 | Temperature activated cytokine release. (a) 
Diagram illustrating the positive feedback circuit used to express IL-
21 (top). Cumulative IL-21 release from 1-hour induction at 37º or 
42ºC. In one sample, doxycycline was removed after 24 hours 
(bottom). (b) Illustration of the constructs used to assay the ability of 
CAR activity to trigger expression of IL-21 in the feedback pHSP 
circuit (top). Cells were either incubated at 37C or thermally 
stimulated for 1 hour at 42ºC with and without bait cells (bottom). 
Media was collected and frozen at each time point and all samples 
were analysed simultaneously at the end of collection. Cumulative 
IL-21 expression was quantified by using an IL-21 ELISA. Error 
bars represent ± SEM. N=3 biological replicates for each sample. 
 
Figure 5 | Dependence of pHSP-driven circuits on T-cell 
activation. (a) Illustration of the constructs used to assay the ability 
of CAR activity to trigger pHSP expression. (b) Cells were either 
incubated at 37ºC, thermally stimulated for 1-hour at 42ºC, or 
incubated with CD19+ bait cells. pHSP triggered activity was 
determined by quantifying GFP expression 24-hours after induction. 
Error bars represent ± SEM. N=3 biological replicates for each 
sample. 
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to chemically terminate the activity of our circuit enhances its 
safety profile in potential therapeutic applications. 
In some scenarios, it would be useful for cytokine 
release to be triggered from a T-cell constitutively expressing a 
CAR, allowing the cytokine to locally boost immune activation 
during CAR-directed killing. To test this possibility, we co-
transduced primary T-cells with our positive IL-21 circuit and 
a constitutively expressed anti-CD19 CAR (Fig. 4b). In the 
absence of target Raji bait cells expressing CD19, IL-21 release 
was well-controlled by thermal induction (Fig. 4b). However, 
co-incubation with bait cells resulted in the activation of IL-21 
release after 3 days in co-culture even in the absence of a 
thermal treatment (Fig. 4b). This result is consistent with the 
induction of pHSP upon T-cell activation, as discussed below. 
 
Dependence of pHSP-driven circuits on T-cell 
activation. To directly examine the possibility that pHSPs 
are turned on in response to CAR-driven T-cell activation, we 
tested the expression of pHSP-driven GFP in constitutively 
CAR-expressing T-cells (Fig. 5a) upon exposure to a thermal 
stimulus or bait cells. We found that both thermal stimulation 
and CAR engagement lead to pHSP-driven gene expression 
(Fig. 5b). This response occurred in cells expressing circuits 
based on HSPB, SynHSPB’3 and HSPmin promoters. Because 
SynHSPB’3 lacks the AP-1 site present in wild-type pHSPs 
such as HSPB, and HSPmin has only HSF1 binding sites, these 
results suggest that pHSP induction takes place via an HSF1-
mediated mechanism. This unexpected finding suggests that 
activated T-cells experience cellular stress – for example due to 
rapid proliferation – potentially resulting in an increased 
number of mis-folded proteins, leading to HSP upregulation. 
This provides an important insight for the design of thermally 
inducible immunotherapies.  
 
Auto-sustained thermally induced CAR 
expression and tumor cell killing.  Our finding that 
CAR engagement drives pHSP activity suggested that a 
simple, auto-sustained gene circuit could drive CAR-mediated 
killing in response to the combination of a thermal stimulus 
and the presence of target cells. In particular, we hypothesized 
that placing CAR expression under the control of a pHSP 
(Fig. 6a) would result in T-cells with no initial CAR expression 
or activity, even in the presence of target cells. Upon thermal 
induction, CAR would become transiently expressed. If the 
CAR target is present in the vicinity of the T-cells, these cells 
would become activated, driving sustained expression of 
additional CAR from the pHSP and target cell killing.  
 
Figure 6 | Auto-sustained thermally induced CAR expression and tumor cell killing. (a) Illustration of the viral construct used 
to assay pHSP expression of CAR-CD19. Cells were either incubated at 37ºC or thermally stimulated for 1 hour at 42ºC and pHSP triggered 
CAR-CD19 expression was quantified by surface staining of an HA tag appended to the CAR 12 hours after induction. N=3 biological 
replicates. (b) CAR-CD19 expression 6, 12, and 24 hours after 1-hour induction with 37ºC or 42ºC. N=3 biological replicates. (c) Illustration 
of the viral construct and assay used to test the ability of pHSP inducible CAR expression to conditionally kill bait cells. Cells were either 
incubated at 37ºC or thermally stimulated for 1 hour at 42ºC before being incubated with CD19+ bait cells. (d) Unmodified T-cells and T-cells 
constitutively expressing CAR-CD19 were used as a negative and positive control respectively. pHSP triggered killing activity was quantified 
by counting the % of bait cells alive compared to the negative control for a duration of 13 days. N= 3 biological replicates for two T-cell 
collections from different patients, total N=6. Error bars represent ± SEM. 
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As predicted, this pHSP-CAR circuit showed no 
baseline CAR expression in primary T-cells, but began to 
express CAR when thermally stimulated (Fig. 6a). CAR 
expression was greatly reduced after 24 hours in the absence of 
target engagement (Fig. 6b). When cultured with CD19+ bait 
cells (Fig. 6c), thermally activated pHSP-CAR T-cells 
eliminated the bait cells after 9 days in co-culture (Fig. 6d). 
This killing was as complete as with positive control T-cells 
carrying a constitutively expressed CAR driven by the EF1α 
promoter, albeit over a longer time span. When pHSP-CAR 
T-cells and bait cells were co-incubated without thermal 
stimulation, no apparent killing took place. These results 
suggest that a thermal stimulus can kick-start a positive 
feedback loop of activation-driven expression of CAR from 
pHSP, leading to effective bait cell elimination.  
 
DISCUSSION 
Our results demonstrate that engineered bioswitch circuits 
using pHSP can provide control of T-cell therapy with mild 
hyperthermia. While it has been previously shown that light-
switchable proteins could also confer spatiotemporal control 
over T-cell activity33, light has poor penetration into tissues, 
limiting the utility of such tools. On the other hand, 
temperature can be elevated at arbitrary depth and with high 
spatial precision using non-invasive methods such as FUS or 
magnetic hyperthermia15–18.  
Our study showed that temperatures in the well-
tolerated range of 37-42ºC can provide control over T-cell 
function, including the synthesis and release of a cytokine and 
the CAR-mediated killing of cancer cells in vitro, with minimal 
baseline activity. In future studies, this performance must be 
characterized in the in vivo setting. 
Despite their name, pHSPs can respond to a variety 
of stimuli such as heat, hypoxia, heavy metals, cytokines and 
cell division34,35. Therefore, the context in which these 
promoters are being used must be carefully considered. In this 
work, we capitalized on non-thermal pHSP induction by the 
T-cell receptor pathway to generate sustained killing circuits. 
In other contexts where the promiscuous responsiveness of 
pHSPs presents an un-exploitable hindrance, it may be 
desirable to develop thermal response mechanisms based on 
orthogonal molecular bioswitches22,23. 
 
MATERIALS AND METHODS 
Plasmid Construction and Molecular Biology 
All plasmids were designed using SnapGene (GSL Biotech) 
and assembled via KLD mutagenesis or Gibson Assembly 
using enzymes from New England Biolabs. After assembly, 
constructs were transformed into NEB Turbo and NEB Stable 
E. coli (New England Biolabs) for growth and plasmid 
preparation. The CAR-CD19 gene containing the CD28 and 
CD3z signaling domain was a kind gift from the Laboratory of 
David Baltimore (Caltech). Integrated DNA Technologies 
synthesized other genes, the pHSP, and all PCR primers.  
 
Cell Lines 
Raji cells (CCL-86) were obtained from ATCC and cultured 
in RPMI 1640 media (Thermo Fisher Scientific) with 1x 
Penicillin/Streptomycin (Corning). GFP+ Raji cells were 
constructed via viral infection of a GFP driven by the EF1a 
promoter. Lentivirus was prepared using a third-generation 
viral vector and helper plasmids (gifts of D. Baltimore). Virus 
was packaged in HEK293T cells grown in 10 cm dishes. After 
3 days of transfection, viral particles were concentrated via 
Ultracentrifugation. Infection was performed by following the 
“RetroNectin” reagent protocol. Experiments were performed 
at least two weeks after infection. 
 
Primary T-cells 
T-cells were isolated with the EasySep Human T-cell isolation 
Kit (STEMCELL Technologies) from frozen human 
peripheral blood mononuclear cells obtained from healthy 
donors. T-cells were stimulated with CD3/CD28 Dynabeads 
(Thermo Fisher Scientific) at 1:1 cell:bead ratio for 1 day 
before viral transduction. T-cells were cultured in RPMI 
supplemented with 50 U/ml IL-2 (Miltenyi Biotech) and 1 
ng/ml IL-15 (Miltenyi Biotech) every other day. Dynabeads 
were removed after 7 days of culture. T-cells were enriched by 
LNGFR magnetic bead based sorting (Miltenyi Biotech) when 
appropriate.   
 
Thermal Regulation Assay 
Thermal stimulation of T-cells was performed in a Bio-Rad 
C1000 thermocycler. T-cells at 1-2 million/ml were 
supplemented with doxycycline, if needed, and mixed well 
before transferring 50 µl into a sterile PCR tube. The 
temperature and duration of stimulation was varied based on 
the experimental procedure. Upon completion of thermal 
stimulation, cells were moved back into a mammalian 
incubator and supplemented 1:1 with fresh media containing 
cytokines and in some cases doxycycline. Cells were typically 
incubated for 24 hours unless stated otherwise before assaying 
with a flow cytometer (MACSQuant VYB). Dead cells were 
typically excluded via FSC/SSC gating for routine assays. In 
figure 2, a LIVE/DEAD viability/cytotoxicity kit (Thermo 
Fisher) was used for a more accurate quantification of cell state. 
Live cells were further gated via a fluorescent protein or 
LNGFR stain to isolate virally infected cells for further 
analysis. The change in mean fluorescence of the cell 
population was used to characterize the fold change of pHSP 
constructs. Anti-HA antibodies (Miltenyi Biotech) were used to 
stain for CAR expression and V450 Mouse Anti-human 
CD271 was used to stain LNGFR. IL-21 expression was 
measured using a human IL-21 DuoSet ELISA (R&D 
systems).  
 
T-cell Bait Assay 
Raji and GFP+ Raji cells were used as bait cells for CAR-CD19 
T-cells. Bait assays were initiated by mixing T-cells with bait 
cells at a 3:1 ratio. This ratio was established to avoid excessive 
bait cell growth before T-cell engagement. To assess T-cell 
killing of bait cells GFP+ Raji were used and the count of GFP+ 
cells was tracked over time. 
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Plasmids will be made available through Addgene upon 
publication. All other materials and data are available from the 
corresponding author upon reasonable request. 
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